FSD Pharma Inc. (HUGE)
| Market Cap | 35.14M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.80M |
| Shares Out | 39.04M |
| EPS (ttm) | -0.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 37,892 |
| Open | 0.908 |
| Previous Close | 0.922 |
| Day's Range | 0.890 - 0.938 |
| 52-Week Range | 0.800 - 2.250 |
| Beta | 0.98 |
| Analysts | Buy |
| Price Target | 7.83 (+770.0%) |
| Earnings Date | May 13, 2022 |
About HUGE
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma In...
Analyst Forecast
According to 7 analysts, the average rating for HUGE stock is "Buy." The 12-month stock price forecast is 7.83, which is an increase of 770.00% from the latest price.
News
FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets
TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio o...
FSD Pharma Announces Dismissal of Derivative Complaint
TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of...
FSD Pharma Announces Engagement with Tekkfund Capital and Share Issuance to Crystal Research Associates
TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech ...
FSD Pharma Appoints Julia Levy Award Recipient David Allan and Dr. John McGraw to Advisory Board
TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio o...
FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari
TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio o...
FSD Pharma Issues Corporate Updates
TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio o...
FSD Pharma Announces Filing of Year-End 2021 Results
TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of...
FSD Pharma Announces Executive Informational Overview Report Produced by Crystal Research Associates LLC
TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio o...
FSD Pharma Announces Agreement for Sale of Cobourg Facility for CAD$16,500,000
TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio o...
FSD Pharma Announces Launch of New Corporate Website
TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio o...
FSD Pharma Congratulates Dr. Eleanor Fish on Being Named to the Order of Canada
TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio o...
FSD Pharma to Present at the H.C. Wainwright Bioconnect Conference on January 10-13th
TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio o...
FSD Pharma Announces Share Repurchase Program
TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio o...
FSD Pharma Establishes New Regulatory Advisory Board with the Appointment of Joga Gobburu, Ph.D., and Mary Melnyk, Ph.D.
TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio o...
FSD Pharma to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th
TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of...
FSD Pharma Unveils Videos Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical M...
TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of...
FSD Pharma Expands Research and Clinical Advisory Board with Appointment of World-Renowned Immunologist and Cytokine ...
TORONTO--(BUSINESS WIRE)---- $HUGE #RestoreFSD--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio o...
FSD Pharma Signs Agreement with Covar Pharmaceuticals to Support the Development of Lucid-PSYCH
TORONTO--(BUSINESS WIRE)---- $HUGE #RestoreFSD--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio o...
FSD Pharma to Present at the KCSA Psychedelics Virtual Investor Conference on October 13th
TORONTO, Oct. 13, 2021 /PRNewswire/ -- FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets ...
FSD Pharma Announces Engagement with Capital Markets Communications Providers and Market Maker
TORONTO--(BUSINESS WIRE)---- $HUGE #RestoreFSD--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio o...
FSD Pharma Announces Closing of Lucid Psycheceuticals Acquisition
TORONTO--(BUSINESS WIRE)---- $HUGE #RestoreFSD--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio o...
Nasdaq-listed FSD Pharma To Advance Psychedelics Pipeline With $9 Million Acquisition Of Lucid Psycheceuticals
FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE), a life sciences holding company looking at cannabinoid and psychedelic-based medicines, announced it is entering a definitive agreement to acquire Lucid Psychec...
FSD Pharma To Buy Canadian Psychedelic Pharmaceutical Firm
FSD Pharma Inc (NASDAQ: HUGE) shares rebounded after falling in premarket on acquiring a Canada-based psychedelic pharmaceutical company. Related: See Why FSD Pharma Terminated COVID-19 Trial
FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals
Acquisition Advances Company's Strategic Plan Toward a Diversified Novel Drug Development Pipeline in Psychedelics and Medical Cannabis Acquisition Advances Company's Strategic Plan Toward a Diversified...
See Why FSD Pharma Terminated COVID-19 Trial
FSD Pharma Inc (NASDAQ: HUGE) will terminate the Phase 2 trial of ultra-micronized palmitoylethanolamide (PEA), or FSD-201, for COVID-19. FSD-201 works by stabilizing mast cells and down-regulates the p...